EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment

Kerstin Wolk iD, Dagmar Wilsmann-Theis, Katrin Witte, Theresa-Charlotte Brembach, Christian Kromer iD, Sascha Gerdes iD, Kamran Ghoreschi iD, Kristian Reich iD, Rotraut Mössner, Robert Sabat iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24021276 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kerstin Wolk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, Celgene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterised by neutrophilic granulocyte (neutrophil)-filled pustules on the palms and soles. The pathogenesis of PPP is poorly understood. This study conducted an identification of the immune mediators associated with PPP and an exploration of apremilast treatment effects on them. We screened for immune mediators elevated in blood taken from 68 patients with PPP versus control participants and included the most promising parameters in the protocol of phase the 2, multicentre study of apremilast (PDE4 inhibitor) in 21 patients with moderate-to-severe PPP (APLANTUS; EudraCT 2016-005122-11) for respective analysis of blood and skin samples of study patients. We investigated stimulated neutrophils and three-dimensional reconstituted epidermis cultures. Interleukin (IL)-19 was found to be the most upregulated immune mediator in the blood of PPP patients. IL-19 serum levels were independent of patients’ age, gender, and BMI but were associated with strongly upregulated cutaneous IL-19 expression and correlated with the number of palmoplantar pustules. In patients participating in the APLANTUS study, apremilast reduced pustules more effectively than erythema and scaling. Moreover, this treatment significantly reduced IL-19 blood and skin levels. The reduction in IL-19 blood levels at week 4 correlated with the reduction in pustule counts at week 20 (end of treatment). IL-19 was expressed by neutrophils activated in vitro and induced CXCL6, a neutrophil-attracting chemokine, in epidermis models. This work demonstrates elevated IL-19 levels in the blood and skin of PPP patients and suggests a relevant role of this cytokine in the appearance of pustules in this disorder. It also suggests the suitability of IL-19 blood levels as a predictive biomarker for the treatment response of PPP patients, which should be validated in further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHumansSkinInterleukinsThalidomide

Stichwörter der Autor:innen

IL-1IL-17chemokinedefensinphosphodiesterase 4small molecule

Substanzen

apremilastInterleukinsThalidomide

Autor:innen und Institutionen

  • Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Department of Dermatology and Allergy, University Medical Center Bonn, 53127 Bonn, Germany.
  • Department of Dermatology, Georg-August-University Goettingen, 37073 Goettingen, Germany.
  • Center for Inflammatory Skin Diseases, Department of Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, 24105 Kiel, Germany.
  • Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.

ORCID-Profile: Kerstin Wolk, Christian Kromer, Sascha Gerdes, Kamran Ghoreschi, Kristian Reich, Robert Sabat

Förderung

  • Novartis
  • Celgene

Zitieren

APA

Wolk, K., Wilsmann-Theis, D., Witte, K., Brembach, T. C., Kromer, C., Gerdes, S., Ghoreschi, K., Reich, K., Mössner, R., & Sabat, R. (2023). Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021276

Vancouver

Wolk K, Wilsmann-Theis D, Witte K, Brembach TC, Kromer C, Gerdes S, et al. Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021276

BibTeX
@article{Wolk2023,
  author = {Wolk, Kerstin and Wilsmann-Theis, Dagmar and Witte, Katrin and Brembach, Theresa-Charlotte and Kromer, Christian and Gerdes, Sascha and Ghoreschi, Kamran and Reich, Kristian and Mössner, Rotraut and Sabat, Robert},
  title = {Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24021276}
}
Kostenlos starten →